Inventor · disambiguated record
Beatrix Stelte-Ludwig
Also filed as: STELTE-LUDWIG BEATRIX
27 granted patents·31 pending applications·232 citations·filing 1998–2024
96Inventor score
Top patents by PatentIndex Score
58 records- 0195US11478554B2Antibody drug conjugates (ADCS) having enzymatically cleavable groupsBayer Pharma AG·Filed 2021·Granted Oct 25, 2022·5 cites·20 claims
- 0294US10973923B2Site specific homogeneous with KSP inhibitorsBayer Pharma AG·Filed 2016·Granted Apr 13, 2021·8 cites·37 claims
- 0394US10022453B2Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)Bayer Pharma AG·Filed 2014·Granted Jul 17, 2018·16 cites·39 claims
- 0492US11643469B2Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodiesBayer Pharma AG·Filed 2022·Granted May 9, 2023·1 cites·15 claims
- 0592US11123439B2Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groupsBayer Pharma AG·Filed 2016·Granted Sep 21, 2021·8 cites·51 claims
- 0692US10744205B2Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodiesBayer Pharma AG·Filed 2016·Granted Aug 18, 2020·9 cites·28 claims
- 0792US8992932B2Binder-drug conjugates (ADCs) and use thereofSEATTLE GENETICS INC·Filed 2012·Granted Mar 31, 2015·26 cites·12 claims
- 0892US6677360B2Biphenyl and biphenyl-analogous compounds as integrin antagonistsBAYER AG·Filed 2001·Granted Jan 13, 2004·29 cites·26 claims
- 0992US6420396B1Biphenyl and biphenyl-analogous compounds as integrin antagonistsBAYER AG·Filed 1999·Granted Jul 16, 2002·59 cites·12 claims
- 1091US11660351B2Antibody drug conjugates (ADCs) having enzymatically cleavable groupsBayer Pharma AG·Filed 2017·Granted May 30, 2023·5 cites·50 claims
- 1190US11001636B2Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodiesBayer Pharma AG·Filed 2017·Granted May 11, 2021·5 cites·15 claims
- 1289US11071788B2Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodiesBayer Pharma AG·Filed 2016·Granted Jul 27, 2021·6 cites·32 claims
- 1389US10485880B2Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodiesBayer Pharma AG·Filed 2015·Granted Nov 26, 2019·11 cites·29 claims
- 1487US11685714B2Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBayer Pharma AG·Filed 2017·Granted Jun 27, 2023·3 cites·30 claims
- 1584US8987209B2N-carboxyalkyl-auristatin and the use thereofLERCHEN HANS-GEORG·Filed 2011·Granted Mar 24, 2015·6 cites·16 claims
- 1682US8722629B2Auristatin derivatives and use thereofLERCHEN HANS-GEORG·Filed 2011·Granted May 13, 2014·3 cites·21 claims
- 1781US9029406B2N-carboxyalkylauristatins and use thereofLERCHEN HANS-GEORG·Filed 2012·Granted May 12, 2015·6 cites·13 claims
- 1881US2023399411A1Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodiesBayer Pharma AG·Filed 2023·Application pending·0 cites
- 1980US2025099600A1Active Metabolites of Kinesin Spindle Protein Inhibitor ConjugatesBayer Pharma AG·Filed 2024·Application pending·0 cites
- 2079US2024376218A1Ccr8 antibodies for therapeutic applicationsBAYER AG·Filed 2024·Application pending·0 cites
- 2179US2024400700A1Ccr8 antibodies for therapeutic applicationsBAYER AG·Filed 2024·Application pending·0 cites
- 2276US2024325553A1Cytostatic conjugates with integrin ligandsBayer Pharma AG·Filed 2024·Application pending·0 cites
- 2375US2023338559A1Antibody drug conjugates (adcs) having enzymatically cleavable groupsBayer Pharma AG·Filed 2023·Application pending·0 cites
- 2473US12059472B2Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBAYER AG·Filed 2017·Granted Aug 13, 2024·1 cites·15 claims
- 2572US12065497B2Methods of treatment using CCR8 antibodiesBAYER AG·Filed 2022·Granted Aug 20, 2024·0 cites·17 claims
- 2671US2021230284A1Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodiesBayer Pharma AG·Filed 2021·Application pending·0 cites
- 2770US2024043379A1Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBayer Pharma AG·Filed 2023·Application pending·0 cites
- 2869US6291503B1β-phenylalanine derivatives as integrin antagonistsBAYER AG·Filed 1999·Granted Sep 18, 2001·25 cites·14 claims
- 2968US12144865B2Antibody drug conjugates with enzymatically cleavable groupsBayer Pharma AG·Filed 2021·Granted Nov 19, 2024·0 cites·33 claims
- 3065US2022362392A1Specific antibody drug conjugates (adcs) having ksp inhibitorsBayer Pharma AG·Filed 2022·Application pending·0 cites
- 3164US11806404B2Site specific homogeneous with KSP inhibitorsBayer Pharma AG·Filed 2021·Granted Nov 7, 2023·0 cites·18 claims
- 3262US2024325366A1Selective cdk9 inhibitor for the treatment of a ras mutant cancerVINCERX PHARMA INC·Filed 2022·Application pending·0 cites
- 3361US11433140B2Specific antibody drug conjugates (ADCs) having KSP inhibitorsBayer Pharma AG·Filed 2017·Granted Sep 6, 2022·0 cites·9 claims
- 3461US2021386864A1Cytostatic conjugates with integrin ligandsBayer Pharma AG·Filed 2019·Application pending·0 cites
- 3561US2015030618A1Novel binder-drug conjugates (adcs) and use thereofSEATTLE GENETICS INC·Filed 2014·Application pending·0 cites
- 3659US2024423973A1Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disordersVINCERX PHARMA GMBH·Filed 2022·Application pending·0 cites
- 3758US2025032477A1Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disordersVINCERX PHARMA GMBH·Filed 2022·Application pending·0 cites
- 3857US2014127240A1Novel Binder-Drug Conjugates (ADCs) and Use of SameLERCHEN HANS-GEORG·Filed 2012·Application pending·0 cites
- 3957US2013122024A1New binder-drug conjugates (adcs) and use thereofLERCHEN HANS-GEORG·Filed 2012·Application pending·0 cites
- 4056US2024408222A1Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorderVINCERX PHARMA GMBH·Filed 2022·Application pending·0 cites
- 4156US2013066055A1New binder-drug conjugates (adcs) and use thereofLERCHEN HANS-GEORG·Filed 2012·Application pending·0 cites
- 4256US2016193359A1New binder-drug conjugates (adcs) and use thereofSEATTLE GENETICS INC·Filed 2016·Application pending·0 cites
- 4354US2015246136A1NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAMESEATTLE GENETICS INC·Filed 2015·Application pending·0 cites
- 4451US2017158775A1Anti-c4.4a antibodies and uses thereofBAYER IP GMBH·Filed 2017·Application pending·0 cites
- 4550US6589972B2β-phenylalanine derivatives as integrin antagonistsBAYER AG·Filed 2001·Granted Jul 8, 2003·0 cites·3 claims
- 4650US2020360531A1Antibody drug conjugates (adcs) with nampt inhibitorsBAYER AG·Filed 2019·Application pending·0 cites
- 4749US2021275686A1Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profileBAYER AG·Filed 2019·Application pending·0 cites
- 4848US7094911B2Biphenyl and biphenyl-analogous compounds as integrin antagonistsBAYER AG·Filed 2002·Granted Aug 22, 2006·0 cites·23 claims
- 4947US2014322220A1Anti-FGFR2 Antibodies and Uses ThereofBAYER IP GMBH·Filed 2012·Application pending·0 cites
- 5046US2005222247A1Chroman derivativesBAYER HEALTHCARE AG·Filed 2004·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →